Literature DB >> 33553071

Case Report: Intracranial Hypertension Secondary to Guillain-Barre Syndrome.

Christina Doxaki1, Eleftheria Papadopoulou1, Iliana Maniadaki1, Nikolaos G Tsakalis2, Konstantinos Palikaras3, Pelagia Vorgia1.   

Abstract

Guillain-Barre Syndrome (GBS), a common cause of acute flaccid paralysis, is characterized by a rapidly progressive, usually symmetric weakness of the extremities. Headache and intracranial hypertension (ICHT) are very rare complications of GBS. Herein we report our current case of an obese girl with typical signs of GBS associated with autonomic dysfunction, cranial nerve deficits and increased intracranial pressure (ICP). We also perform a systematic study presenting and discussing previous case reports of GBS associated with ICHT, papilledema or hydrocephalus, highlighting the differences of the current case compared to previous studies. Although intracranial hypertension is a rare complication of pediatric GBS, clinicians should promptly detect it. Obesity may be a predisposing factor, given the strong association between idiopathic intracranial hypertension (IIH) and weight gain. Neurological evaluation, fundus examination and low threshold for intracranial imaging should be an integral part of medical practice in case of obesity, headache or visual changes in GBS patients.
Copyright © 2021 Doxaki, Papadopoulou, Maniadaki, Tsakalis, Palikaras and Vorgia.

Entities:  

Keywords:  Guillain–Barre syndrome; headache; hydrocephalus; intracranial hypertension; papilledema

Year:  2021        PMID: 33553071      PMCID: PMC7857149          DOI: 10.3389/fped.2020.608695

Source DB:  PubMed          Journal:  Front Pediatr        ISSN: 2296-2360            Impact factor:   3.418


  57 in total

Review 1.  New concepts of Guillain-Barré syndrome.

Authors:  A K Asbury
Journal:  J Child Neurol       Date:  2000-03       Impact factor: 1.987

2.  Papilledema and hydrocephalus associated with recurrent polyneuritis. Guillian-Barré type.

Authors:  R Janeway; D L Kelly
Journal:  Arch Neurol       Date:  1966-11

3.  Papilledema in Guillain-Barré syndrome. A case report.

Authors:  K Farrell; A Hill; S Chuang
Journal:  Arch Neurol       Date:  1981-01

4.  Benign intracranial hypertension: atypical presentation of Miller Fisher syndrome?

Authors:  Leena D Mewasingh; Tayeb Sékhara; Bernard Dachy; Maurice C Djeunang; Bernard Dan
Journal:  Pediatr Neurol       Date:  2002-03       Impact factor: 3.372

Review 5.  Posterior reversible encephalopathy syndrome in Guillain-Barré syndrome.

Authors:  Adam Chen; Jennifer Kim; Galen Henderson; Aaron Berkowitz
Journal:  J Clin Neurosci       Date:  2015-03-20       Impact factor: 1.961

Review 6.  Plasma exchange for Guillain-Barré syndrome.

Authors:  J C Raphaël; S Chevret; R A Hughes; D Annane
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Systematic reviews of treatment for inflammatory demyelinating neuropathy.

Authors:  R A C Hughes
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

8.  Complications of apheresis in children.

Authors:  Bruno Michon; Albert Moghrabi; Rochelle Winikoff; Stéphane Barrette; Mark L Bernstein; Josette Champagne; Michèle David; Michel Duval; Heather A Hume; Nancy Robitaille; André Bélisle; Martin A Champagne
Journal:  Transfusion       Date:  2007-10       Impact factor: 3.157

9.  Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management.

Authors:  Matthew J Thurtell; Michael Wall
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

Review 10.  Diagnosis and management of Guillain-Barré syndrome in ten steps.

Authors:  Sonja E Leonhard; Melissa R Mandarakas; Francisco A A Gondim; Kathleen Bateman; Maria L B Ferreira; David R Cornblath; Pieter A van Doorn; Mario E Dourado; Richard A C Hughes; Badrul Islam; Susumu Kusunoki; Carlos A Pardo; Ricardo Reisin; James J Sejvar; Nortina Shahrizaila; Cristiane Soares; Thirugnanam Umapathi; Yuzhong Wang; Eppie M Yiu; Hugh J Willison; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2019-09-20       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.